LEAP 2: Oral Lefamulin Demonstrates Favorable Safety, Tolerability for Patients With CABP
April 16th 2019Lefamulin demonstrated non-inferiority when compared with moxifloxacin, and both treatment arms reported a low rate of serious treatment-emergent AEs or treatment-emergent AEs leading to discontinuation.
Read More
Cloudbreak Antiviral Conjugate Demonstrates Potent In Vitro Activity
April 16th 2019Cidara Therapeutics has developed CB-012, a stable conjugate of a highly potent antiviral agent linked to human IgG1 Fc, and investigators are evaluating the asset for the treatment and prevention of seasonal and pandemic influenza A and B infections.
Read More